Артериальная гипертензия и дислипидемия при желчно-каменной болезни ирина Николаевна григорьева1

1999 г. такой ассоциации не найдено. Гипоальфахолестеринемия и гипертриглицеридемия являются общими факторами риска для желчно-каменной болезни и артериальной гипертензии. Однако наличие артериальной гипертензии у больных с желчно-каменной болезнью, по данным нашего эпидемиологического исследования, не сопровождалось изменением липидного профиля.

2. Григорьева И.Н., Никитин Ю.П. Липидный обмен и желчнокаменная болезнь. Новосибирск, 2005. 176 с.

3. Григорьева И.Н. Урсодезоксихолевая кислота во внутренней медицине. М., 2012. 152 с.

4. Колпаков Н.А. Этиопатогенез, диагностика и хирургическое лечение желчнокаменной болезни у больных молодого возраста: автореф. дис. … канд. мед. наук. СПб., 1993.

5. Максимов В.А., Далидович К.К., Чернышев А.Л. и др. Современная терапия заболеваний органов пищеварения. М., 2011. 712 с.

6. Максимов В.Н. Связь наследственной отягощенности и полиморфизма некоторых генов-кандидатов с сердечно-сосудистыми заболеваниями и их факторами риска в городской популяции Западной Сибири: автореф. дис. … докт. мед. наук. Новосибирск, 2007.

7. Минеева Л.С. Оптимизация санаторного лечения больных, оперированных по поводу желчно- каменной болезни: автореф. дис. … канд. мед. наук. М., 2008.

8. Николаева А.Г., Гирса В.Н., Немцов В.Н. Вегетотропная терапия и гипобарическая гипоксическая адаптация у больных с дисмоторикой желчного пузыря // Эксперим. клинич. гастроэнтерол. 2007. (3). 4–8.

9. Осипенко М.Ф., Волошина Н.Б., Литвинова Н.В. Последствия оперативного лечения желчно-каменной болезни // Практическая медицина. 2012. 3. (12). 25–31.

10. Парцерняк С.А. Вегетозы. СПб., 1999. 176 с.

11. Петухов В.А., Кузнецов М.Р., Лисин С.В. Желчнокаменная болезнь и беременность: причинно-следственные взаимосвязи // Анн. хирургии. 1998. (2). 14–21.

12. Чазова И.Е. Кардиология: национальное руководство / Ред. Ю.Н. Беленков, Р.Г. Оганов. М., 2010. 563–574.

13. Шульпекова, Ю.О., Драпкина О.М., Ивашкин В.Т. Абдоминальный болевой синдром // Рос. журн. гастроэнтерол. гепатол. колопроктол. 2002. 12. (4). 8–15.

14. Ahmed M.H., Hamad M.A., Routh C., Connolly V. Statins as potential treatment for cholesterol gallstones: an attempt to understand the underlying mechanism of actions // Expert. Opin. Pharmacother. 2011. 12. (17). 2673–2681.

15. Amigo L., Quicones V., Leiva A. et al. Apolipoprotein A-I deficiency does not affect biliary lipid secretion and gallstone formation in mice // Liver Int. 2011. 31. (2). 263–271.

16. Angelin B., Holmquist L., Leijd B. et al. Bile acid metabolism in familial disbetalipoproteinaemia: studies in subjects with the apolipoprotein E 2/2 phenotype // Eur. J. Clin. Invest. 1990. 20. 143–149.

17. Attili A.F., Carulli N., Roda E. et al. Epidemiology of gallstone disease in Italy: prevalence data of the Multicenter Italian Study on Cholelithiasis (M.I.COL.) // Am. J. Epidemiol. 1995. 141. 2. 158–165.

18. Bennet A.M., Di A.E., Ye Z. et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk // JAMA. 2007. 298. (11). 1300–1311.

19. Bennion L.J., Drobny E., Knowler W.C. et al. Sex differences in the size of bile acid pools // Metabolism. 1978. 27. (8). 961–969.

20. Bertomeu A., Ros E., Zambon D. et al. Apolipoprotein E polymorphism and gallstones // Gastroenterology. 1996. 111. 1603–1610.

21. Boland L.L., Folsom A.R., Boerwinkle E. et al. Atherosclerosis Risk in Communities (ARIC) Study Investigators. Apolipoprotein E genotype and gallbladder disease risk in a large population-based cohort //Ann. Epidemiol. 2006. 16. (10). 763–769.

22. Cariati A., Piromali E. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease // Expert. Opin. Pharmacother. 2012. 13. (9). 1223–1227.

23. Chavez-Tapia N.C., Kinney-Novelo I.M., Sifuentes-Renteria S.E. et al. Association between cholecystеctomy for gallstone disease and risk factors for cardiovascular disease // Annals of Hepatology. 2012. 11. (1). 85–89.

24. Chen C.Y., Lu C.L., Lee P.C. et al. The risk factors for gallstone disease among senior citizens: an Oriental study // Hepatogastroenterol. 1999. 46. (27). P.1607–1612.

25. Cho J.Y., Han H.S., Yoon Y.S., Ahn K.S. Risk factors for acute cholecystitis and a complicated clinical course in patients with symptomatic cholelithiasis // Arch. Surg. 2010. 145. (4). 329–333.

26. Coelho J.C., Bonilha R., Pitaki S.A. et al. Prevalence of gallstones in a Brazilian population // Int. Surg. 1999. 84. (1). 25–28.

27. Cojocaru C., Pandele G.I. Metabolic profile of patients with cholesterol gallstone disease // Rev. Med. Chir. Soc. Med. Nat. Iasi. 2010. 114. (3). 677–82.

28. Cynthia C.W.Ko., Beresford S.A.A., Alderman B. et al. Apolipoprotein E genotype and the risk of gallbladder disease in pregnancy // Hepatology. 2000. 31. (1). 18–23.

29. Dixit M., Choudhuri G., Mittal B. Association of APOE-C1 gene cluster polymorphisms with gallstone disease // Dig. Liver Dis. 2006. 38. (6). 397–403.

30. Everson G.T. Liver problems in pregnancy: distinguishing normal from abnormal hepatic changes // Medscape. Womens. Health. 1998. 3. (2). 3–5.

31. Fischer S., Dolu M.H., Zündt B. et al. Apolipo- protein E polymorphism and lithogenic factors in gallbladder bile // Eur. J. Clin. Inves. 2001. 31. (9). 789–795.

32. George E.D., Schluger L.K. Special women’s health issues in hepatobiliary diseases // Clin. Fam. Pract. 2000. 2. 155–169.

33. Gylling H., Kontula K., Miettinen T.A. Cho- lesterol absorption and metabolism and LDL kinetics in healthy men in different apoprotein E phenotypes and apoprotein B Xba I and LDL receptor Pvu II genotypes // Arterioscler. Thromb. Vasc. Biol. 1995. 15. 208–213.

34. Hasegawa K., Terada S., Kubota K. et al. Effect of apolipoprotein E polymorphism on bile lipid com- position and the formation of cholesterol gallstone // Am. J. Gastroenterol. 2003. 98. (7). 1605–1609.

35. Hatters D.M., Peters-Libeu C.A., Weisgra- ber K.H. Apolipoprotein E structure: insights into function // Trends Biochem. Sci. 2006. 31. (8). 445–454.

36. Jiang Z.Y., Han T.Q., Suo G.J. et al. Po- lymorphisms at cholesterol 7α-hydroxylase, apolipoproteins B and E and low density lipoprotein receptor genes in patients with gallbladder stone disease // World J. Gastroenterol. 2004. 10. (10). 1508–1512.

37. Juvonen T., Kervinen K., Kairaluoma M.I., Kesäniemi Y.A. Effect of cholecystectomy on plasma lipid and lipoprotein levels // Hepatogastroenterol. 1995. 42. (4). 377–382.

38. Kesaniemi Y.A., Ehnholm C., Miettinen T.A. Intestinal cholesterol absorbtion efficiency is related to apolipoprotein E phenotype // J. Clin. Invest. 1987. 80. 578–581.

39. Kim S.S., Lee J.G., Kim D.W. et al. Insulin resistance as a risk factor for gallbladder stone formation in Korean postmenopausal women // Korean J. Intern. Med. 2011. 26. (3). 285–293.

40. Kim S.W., Park Y.H., Choi J.W. Clinical and epidemiological analysis of 10-year experienced 1,719 gallstone patients // Korean J. Gastroenterol. 1993. 25. 159–167.

41. Lin Q.Y., Du J.P., Zhang M.Y. et al. Effect of apolipoprotein E gene Hha I restricting fragment length polymorphism on serum lipids in cholecystolithiasis // World J. Gastroenterol. 1999. 5. (3). 228–230.

42. Li X., Du Y., Du Y. et al. Association of apolipoprotein E gene polymorphism with essential hypertension and its complications // Clin. Exp. Med. 2003. 2. (4). 175–179.

43. Malik A.A., Wani M.L., Tak S.I. et al. Associa- tion of dyslipidaemia with cholilithiasis and effect of cholecystectomy on the same // Int. J. Surg. 2011. 9. (8). 641–642.

44. Mendez-Sanchez N., Bahena-Aponte J., Chavez- Tapia N.C. et al. Strong association between gallstones are cardiovascular disease // Am. J. Gastroenterol. 2005. 100. 827–830.

45. Mendez-Sanchez N., Chavez-Tapia N.C., Motola-Kuba D. et al. Metabolic syndrome as a risk factor for gallstone disease // World J. Gastroenterol. 2005. 11. (11). 1653–7.

46. Mendez-Sanchez N., Zamora-Valdes D., Flores- Rangel J.A. et al. Gallstones are associated with carotid atherosclerosis // Liv. Int. 2008. 28. 402–406.

47. Miettinen T.A. Impact of Apo E phenotype on the regulation of cholesterol metabolism // Ann. Med. 1991. 23. 181–186.

48. Molinari C., Grossini E., Mary D.A., Vacca G. Effect of distension of the gallbladder on plasma renin activity in anesthetized pigs // Circulation. 2000. 101. (21). 2539–2545.

49. Muhammad N., Rahimnajjad N.A., Rahimnaj- jad M.K. et al. Assessment of Characteristics of Patients with Cholilithiasis from economically deprived Rural Localities // BMC Res. Notes. 2012. 5. (1). 334.

50. Newman P.P. Changes in arterial blood pressure following stimulation of the gallbladder // Visceral Afferent Functions of the Nervous System / Ed. P.P. Newman. London, 1974. 35–37.

51. Nilsson E., Fored C.M., Granath F. et al. Cholecystectomy in Sweden 1987–99: a nationwide study of mortality and preoperative admissions // Scand. J. Gastroenterol. 2005. 40. (12). 1478–1485.

52. Ordway G.A., Longhurst J.C. Cardiovascular reflexes arising from the gallbladder of the cat: effects of capsaicin, bradykinin, and distension // Circ. Res. 1983. 52. 26–35.

53. Petitti D.B., Sidney S., Perlman J.A. Increased risk of cholecystectomy in users of supplemental estrogen // Gastroenterol. 1988. 94. 91–95.

54. Portincasa P., van Erpecum K.J., van de Meeberg P.C. et al. Apolipoprotein E genotype and gallbladder motility influence speed of gallstone clea- rance and risk of recurrence after extracorporeal shock- wave lithotripsy // Hepatology. 1996. 24. 580–587.

55. Sama C., LaRusso N.F. Effect of deoxycholic, chenodeoxycholic and cholic acids on intestinal absorbtion of cholesterol in humans // Mayo Clin. Proc. 1982. 57. 44–50.

56. Sengupta S., Modak P., McCauley N., O’Don- nell L.J. Prokinetic effect of alpha-adrenergic antagonist, and beta-adrenergic antagonist on gall-bladdermotility in humans with gall-stone disease // Eur. J. Gastroenterol. Hepatol. 2007. 19. (7). 581–583.

57. Shaffer E.A. Gallstone disease: epidemiology of gallbladder stone disease // Best Pract. Res. Clin. Gastroenterol. 2006. 20. 981–996.

58. Smelt A.H. Triglycerides and gallstone forma- tion // Clin.Chim.Acta. 2010. 411. (21–22). 1625–1631.

59. Song Y., Stampfer M.J., Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease // Ann. Intern. Med. 2004. 141. (2). 137–147.

60. Thijs C., Knupschild P., Brombaher P. Serum lipids and gallstones: a case-control study // Gastroenterol. 1990. 99. (3). 843–849.

61. Tsai C.J., Leitzmann M.F., Willett W.C., Giovannucci E.L. Statin use and the risk of cholecystectomy in women // Gastroenterol. 2009. 136. (5). 1593–1600.

62. Uhler M.L., Marks J.W., Judd H.L. Estrogen replacement therapy and gallbladder disease in postmenopausal women // Menopause. 2000. 7. (3). 162–167.

63. Van Erpecum K.J., Portincasa P., Dohlu M.H. et al. Biliary pronucleating proteins and apolipoprotein E in cholesterol and pigmentstone patients // J. Hepatol. 2003. 39. (1). 7–11.

64. Van Erpecum K.J., Portincasa P., Eck- hardt E.R.M. et al. Increased risk of cholesterol gall- stone formation in subjects with apolipoprotein E4 genotype: its relation to bile composition and crys- tallization // Gastroenterol. 1998. 114. (4). A547.

65. Weintraub M.S., Eisenberg S., Breslow J.L. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E // J. Clin. Invest. 1987. 80. 1571–1577.

66. Wilson P.W., Schaefer E.J., Larson M.G. et al. Apolipoprotein E alleles and risk of coronary disease. A meta-analysis // Arterioscler. Thromb. Vasc. Biol. 1996. 16. (10). 1250–1255.

67. Wysowski D.K., Goldberg E.L., Comstock G.W., Diamond E.L. A study of a possible association between breast cancer and gallbladder disease // Am. J. Epidemiol. 1986. 123. (3). 532–543.

68. Xu Q., Tao L.Y., Wu Q. et al. Prevalences of and risk factors for biliary stones and gallbladder polyps in a large Chinese population // HPB (Oxford). 2012. 14. (6). 373–381.

69. Yang S.H., Lee S.E., Jang J.Y. et al. Clinical and epidemiological analysis of gallstone patients focused on 25-year experience of surgically treated patients // Korean J. Gastroenterol. 2007. 50. (1). 42–50.

70. Yoo E.-H., Lee S.-Y. The prevalence and risk factors for gallstone disease // Clin. Chem. Lab. Med.